Overview

Study to Evaluate the PK of Single and Optional Multiple Dosing Regimens of MR Formulations of PCS499 Compared to Trental® Administered to Healthy Subjects

Status:
Completed

Trial end date:
2018-06-04

Target enrollment:

Participant gender:

Summary

This was a Phase I, single centre, open-label, non-randomised study and was designed to be conducted in up to 2 parts. The purpose of Part 1 was to identify a MR formulation of PCS499 that would provide an optimal dosing regimen in patients. The purpose of Part 2 of the study was to generate repeat dose information for the selected MR formulation of PCS499 in order to provide additional PK information for future patient studies.

Phase:

Phase 1

Details

Lead Sponsor:

Processa Pharmaceuticals

Collaborator:

Quotient Sciences

Treatments:

Pentoxifylline